Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial results

The all-oral combination of ixazomib, cyclophosphamide, and dexamethasone (ICD) is well tolerated and effective in newly diagnosed and relapsed multiple myeloma (MM). We carried out MUKeight, a randomised, controlled, open, parallel group, multi-centre phase II trial in patients with relapsed MM aft...

Descripción completa

Detalles Bibliográficos
Autores principales: Auner, Holger W., Brown, Sarah R., Walker, Katrina, Kendall, Jessica, Dawkins, Bryony, Meads, David, Morgan, Gareth J., Kaiser, Martin F., Cook, Mark, Roberts, Sadie, Parrish, Christopher, Cook, Gordon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8972903/
https://www.ncbi.nlm.nih.gov/pubmed/35365598
http://dx.doi.org/10.1038/s41408-022-00626-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8972903/
https://www.ncbi.nlm.nih.gov/pubmed/35365598
http://dx.doi.org/10.1038/s41408-022-00626-4

Ejemplares similares